Jordan Schecter

VP, Multiple Myeloma at Johnson & Johnson

Speaker

Jordan M Schecter, MD is currently the Vice President for the Multiple Myeloma Disease Area Stronghold at Johnson & Johnson; Research and Development. In this role, he is responsible for the end-to-end Multiple Myeloma strategy from early discovery, translational research, early development, late development, and post-commercialization strategy. Prior to assuming this role in January 2024, he was the global clinical leader for Ciltacabtagene Autoleucel (CARVYKTI ®) an approved CAR-T therapy for Relapsed Multiple Myeloma).

Previous to this role, Dr. Schecter was the co-Clinical lead for Daratumumab (Darzalex ®), a monoclonal antibody first approved in 2015 for the treatment of Multiple Myeloma. Prior to joining Janssen, Dr. Schecter was an associate professor of medicine at Columbia University Medical Center in New York City where he was involved in clinical research for Multiple Myeloma and AL Amyloidosis. He earned his M.D. at Warren Alpert Medical School and completed his internship at Rhode Island Hospital, both at Brown University, and completed his residency and a fellowship in medical hematology and oncology at Columbia University Medical Center in New York City.